Jeffrey Holford

Jeffrey Holford Recent News

Court Date For Litigation With Amgen And Other Expectations For AbbVie
|
Jefferies Sees Much Larger Market Opportunity For AstraZeneca, Upgrades To Buy
|
Jefferies Shares Pharma Stock Catalyst Outlook
|
Amid Few Catalysts, Jefferies Downgrades AstraZeneca
|
Jefferies Says It's Buying Abbott Labs Stock On Emerging Market Growth, Valuation
|
New Report: Abbvie Is Jefferies' Top Global Pharma Stock
|
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
|
Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown
|
A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea
|
Jefferies Raises Zoetis Price Target, Says Consolidation Continues To Look Likely
|
UPDATE: Jefferies Lowers PT on Zoetis on Challenges Ahead
|
UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead
|
UPDATE: Jefferies Raises PT on Johnson & Johnson on Challenges Ahead
|
UPDATE: Jefferies Downgrades Bristol-Myers Squibb on Challenges Ahead
|
UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review
|
UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review
|
UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review
|
UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved